AU2018218521C1 - Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer - Google Patents
Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer Download PDFInfo
- Publication number
- AU2018218521C1 AU2018218521C1 AU2018218521A AU2018218521A AU2018218521C1 AU 2018218521 C1 AU2018218521 C1 AU 2018218521C1 AU 2018218521 A AU2018218521 A AU 2018218521A AU 2018218521 A AU2018218521 A AU 2018218521A AU 2018218521 C1 AU2018218521 C1 AU 2018218521C1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- cancers
- cancer
- compounds
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455644P | 2017-02-07 | 2017-02-07 | |
| US62/455,644 | 2017-02-07 | ||
| US201762594784P | 2017-12-05 | 2017-12-05 | |
| US62/594,784 | 2017-12-05 | ||
| PCT/GB2018/050345 WO2018146471A1 (en) | 2017-02-07 | 2018-02-07 | Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2018218521A1 AU2018218521A1 (en) | 2019-08-15 |
| AU2018218521B2 AU2018218521B2 (en) | 2021-11-25 |
| AU2018218521C1 true AU2018218521C1 (en) | 2022-06-09 |
Family
ID=61231287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018218521A Ceased AU2018218521C1 (en) | 2017-02-07 | 2018-02-07 | Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11168069B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3580209A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020506244A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20190115012A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110382480A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018218521C1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019016233A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3051538A1 (cg-RX-API-DMAC7.html) |
| MA (1) | MA47452A (cg-RX-API-DMAC7.html) |
| MX (1) | MX389800B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018146471A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| CN110382486A (zh) | 2017-02-07 | 2019-10-25 | 欧比力克治疗公司 | 杂芳磺酰基取代的吡啶和其在癌症治疗中的用途 |
| US11208384B2 (en) | 2017-02-07 | 2021-12-28 | Oblique Therapeutics Ab | Sulfinylpyridines and their use in the treatment of cancer |
| KR20190115014A (ko) | 2017-02-07 | 2019-10-10 | 오블리크 세러퓨틱스 에이비 | 하이드로카르빌설포닐-치환된 피리딘 및 암의 치료에서 이의 용도 |
| US20210038577A1 (en) * | 2018-02-12 | 2021-02-11 | Cinda Pharma Ab | Thioredoxin reductase inhibitors for use in the treatment of cancer |
| WO2020061101A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
| JP7425793B2 (ja) | 2018-10-29 | 2024-01-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピリジニルスルホンアミド誘導体、医薬組成物およびそれらの使用 |
| WO2020089026A1 (en) | 2018-10-29 | 2020-05-07 | Boehringer Ingelheim International Gmbh | Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof |
| KR20240067583A (ko) | 2022-11-09 | 2024-05-17 | 한국생산기술연구원 | 정전압 압전기화학 분석 방법 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0031173A1 (en) * | 1979-12-19 | 1981-07-01 | Duphar International Research B.V | New nitrothiophenes, method of preparing the new compounds, as well as fungicidal and/or bactericidal compositions on the basis of the new compounds |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU543161B2 (en) | 1980-03-07 | 1985-04-04 | E.I. Du Pont De Nemours And Company | Pyrimidine or s.triazine derivatives |
| US4456469A (en) | 1980-03-07 | 1984-06-26 | E. I. Du Pont De Nemours And Company | Pyridyl sulfone herbicides |
| US4791127A (en) | 1985-10-07 | 1988-12-13 | Nippon Kayaku Kabushiki Kaisha | Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides |
| DE3812177A1 (de) | 1988-04-13 | 1989-10-26 | Bayer Ag | 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung |
| AU2395095A (en) | 1994-04-29 | 1995-11-29 | G.D. Searle & Co. | Method of using (h+/k+) atpase inhibitors as antiviral agents |
| WO1997008147A1 (de) | 1995-08-24 | 1997-03-06 | Basf Aktiengesellschaft | N-heterocyclische verbindungen, zwischenprodukte für ihre herstellung, sie enthaltende mittel und ihre verwendung zur bekämpfung von schadpilzen |
| DE19531148A1 (de) | 1995-08-24 | 1997-02-27 | Basf Ag | Fungizide Pyridin-2-yl-Derivate |
| US6191280B1 (en) | 1997-05-30 | 2001-02-20 | Basf Aktiengesellschaft | Method for producing substituted thiopyridines |
| US6284923B1 (en) | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
| WO1999018096A1 (en) | 1997-10-02 | 1999-04-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6191170B1 (en) | 1998-01-13 | 2001-02-20 | Tularik Inc. | Benzenesulfonamides and benzamides as therapeutic agents |
| ATE236136T1 (de) | 1998-01-16 | 2003-04-15 | Hoffmann La Roche | Benzosulfonderivate |
| ATE311366T1 (de) | 2000-02-29 | 2005-12-15 | Millennium Pharm Inc | Benzamide und ähnliche inhibitoren vom faktor xa |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| WO2003068744A1 (en) | 2002-02-18 | 2003-08-21 | Ishihara Sangyo Kaisha, Ltd. | Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same |
| US20030236287A1 (en) | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
| US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
| EP1651595A2 (en) | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| CA2568451A1 (en) | 2004-06-04 | 2005-12-22 | Arena Pharmaceuticals, Inc. | Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| US20060019967A1 (en) | 2004-07-21 | 2006-01-26 | Su-Ying Wu | SARS CoV main protease inhibitors |
| GB0426313D0 (en) | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2006083692A2 (en) | 2005-01-28 | 2006-08-10 | Mount Sinai Schoool Of Medicine | Methods of identifying modulators of bromodomains |
| GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
| EP1976495A2 (en) | 2006-01-06 | 2008-10-08 | Aarhus Universitet | Compounds acting on the serotonin transporter |
| JP2009535307A (ja) | 2006-04-28 | 2009-10-01 | アベキサ・リミテッド | インテグラーゼ阻害剤３ |
| CA2687451A1 (en) * | 2006-05-22 | 2007-11-29 | Thioredoxin Systems Ab | Bacterial thioredoxin reductase inhibitors and methods for use thereof |
| JP2010533729A (ja) | 2007-07-17 | 2010-10-28 | プレキシコン，インコーポレーテッド | キナーゼ調節のための化合物と方法、及びそのための適応 |
| CN101723932B (zh) | 2008-10-31 | 2013-11-20 | 北京以岭生物工程技术有限公司 | 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途 |
| CA2763589A1 (en) * | 2009-05-28 | 2010-12-02 | President And Fellows Of Harvard College | N,n'-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation |
| NZ713361A (en) | 2009-08-17 | 2017-06-30 | Memorial Sloan Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
| JP5850321B2 (ja) | 2010-02-10 | 2016-02-03 | 公立大学法人横浜市立大学 | 神経選択的転写抑制因子ＮＲＳＦに特異的に結合するｍＳｉｎ３Ｂに結合する化合物の利用 |
| EP2536411A4 (en) * | 2010-02-18 | 2013-08-07 | Univ Princeton | HEMMER OF THE METABOLISM OF LOW-CHAIN AND VERY LOW-FATTYED FATTY ACIDS AS AN ANTIVIRUS ACTIVE SUBSTANCES WITH A WIDE SPECTRUM |
| CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
| EP2609089A1 (en) | 2010-08-27 | 2013-07-03 | Universität des Saarlandes | Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| US9539256B2 (en) | 2012-02-10 | 2017-01-10 | The Board Of Regents Of The University Of Texas System | Modulators of exchange proteins directly activated by cAMP (EPACS) |
| EP3019509B1 (en) | 2013-07-10 | 2019-09-11 | Boehringer Ingelheim International GmbH | Novel chiral nitrogen-phosphorus ligands and their use for asymmetric hydrogenation of alkenes |
| CN104672214B (zh) | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| CN105503827B (zh) | 2014-10-11 | 2019-09-24 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备方法和用途 |
| CN105085483B (zh) | 2015-06-04 | 2019-01-01 | 湖北生物医药产业技术研究院有限公司 | 激酶抑制剂及其应用 |
| CN104987324B (zh) | 2015-06-04 | 2018-05-04 | 湖北生物医药产业技术研究院有限公司 | 作为alk抑制剂的嘧啶衍生物 |
| GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
| US11208384B2 (en) | 2017-02-07 | 2021-12-28 | Oblique Therapeutics Ab | Sulfinylpyridines and their use in the treatment of cancer |
| CN110382486A (zh) | 2017-02-07 | 2019-10-25 | 欧比力克治疗公司 | 杂芳磺酰基取代的吡啶和其在癌症治疗中的用途 |
| KR20190115014A (ko) | 2017-02-07 | 2019-10-10 | 오블리크 세러퓨틱스 에이비 | 하이드로카르빌설포닐-치환된 피리딘 및 암의 치료에서 이의 용도 |
-
2018
- 2018-02-07 US US16/483,961 patent/US11168069B2/en not_active Expired - Fee Related
- 2018-02-07 MA MA047452A patent/MA47452A/fr unknown
- 2018-02-07 BR BR112019016233A patent/BR112019016233A2/pt not_active IP Right Cessation
- 2018-02-07 CN CN201880010203.5A patent/CN110382480A/zh active Pending
- 2018-02-07 JP JP2019563698A patent/JP2020506244A/ja active Pending
- 2018-02-07 CA CA3051538A patent/CA3051538A1/en active Pending
- 2018-02-07 WO PCT/GB2018/050345 patent/WO2018146471A1/en not_active Ceased
- 2018-02-07 KR KR1020197024690A patent/KR20190115012A/ko not_active Ceased
- 2018-02-07 MX MX2019009354A patent/MX389800B/es unknown
- 2018-02-07 AU AU2018218521A patent/AU2018218521C1/en not_active Ceased
- 2018-02-07 EP EP18705719.5A patent/EP3580209A1/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0031173A1 (en) * | 1979-12-19 | 1981-07-01 | Duphar International Research B.V | New nitrothiophenes, method of preparing the new compounds, as well as fungicidal and/or bactericidal compositions on the basis of the new compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3051538A1 (en) | 2018-08-16 |
| US20200024255A1 (en) | 2020-01-23 |
| EP3580209A1 (en) | 2019-12-18 |
| BR112019016233A2 (pt) | 2020-04-07 |
| RU2019127886A (ru) | 2021-03-10 |
| MX2019009354A (es) | 2019-09-19 |
| MA47452A (fr) | 2019-12-18 |
| AU2018218521A1 (en) | 2019-08-15 |
| WO2018146471A1 (en) | 2018-08-16 |
| KR20190115012A (ko) | 2019-10-10 |
| MX389800B (es) | 2025-03-20 |
| CN110382480A (zh) | 2019-10-25 |
| RU2019127886A3 (cg-RX-API-DMAC7.html) | 2021-05-17 |
| AU2018218521B2 (en) | 2021-11-25 |
| JP2020506244A (ja) | 2020-02-27 |
| US11168069B2 (en) | 2021-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018218521C1 (en) | Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| AU2018218522B2 (en) | Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| US11208384B2 (en) | Sulfinylpyridines and their use in the treatment of cancer | |
| AU2018218519B2 (en) | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer | |
| CA2995077C (en) | Pyridines and their use in the treatment of cancer | |
| TW201144323A (en) | Amino-oxazines and amino-dihydrothiazine compounds as Beta-secretase modulators and methods of use | |
| TW202328130A (zh) | Sik抑制劑及其組合物、製備方法和用途 | |
| US11110089B2 (en) | Pyridazinones and their use in the treatment of cancer | |
| RU2777596C2 (ru) | Гетероциклилсульфонил-замещенные пиридины и их применение при лечении рака |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 FEB 2022 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 10 FEB 2022 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |